ClinicalTrials.gg
Enrolling by invitationNCT06831331NUTRAUpdated Oct 23, 2026

Nutrition in Rheumatoid Arthritis

An interventional study of Healthy diet based on NNR2023 and Control/waiting-list in Rheumatoid Arthritis (RA), sponsored by Vastra Gotaland Region. Enrolling by invitation at 1 site in Sweden. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Vastra Gotaland Region · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region — 2 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Vastra Gotaland Region.

Started
2025
the only one that year
No phase
5 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, this one is the only one that started in 2025, is one of 5 with no phase, and was the 11th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Arthritis, Rheumatoid by Vastra Gotaland Region, or all of them as a file.
02

Study summary

Background: Individuals with Rheumatoid Arthritis (RA) often experience persistent symptoms such as pain and stiffness despite modern pharmacological treatments. They also have an increased risk of cardiovascular disease. Elevated risk factors for cardiovascular disease limit the options for some symptom-relieving medications, making a reduction in these risk factors highly desirable. Diet has been shown to reduce several of these factors, but the scientific evidence for rheumatoid arthritis is limited, and thus tailored dietary advice is lacking.

Objective: The purpose of the NUTRA study is to evaluate the effect of a diet that follows the updated Nordic Nutrition Recommendations (2023) on disease activity and cardiovascular risk factors in individuals with diagnosed RA. Specifically, the study will analyze the impact of the diet on clinically relevant markers such as blood pressure, lipid profile, inflammatory markers, and body composition.

Study Plan: The study will include about 120 patients, and participants will be randomized into either an immediate 3-month diet intervention following the Nordic Nutrition recommendations or a waitinglist control group, that will start with the diet intervention after three months. The intervention diet, will be added as a complementary treatment to the medications the patients are already taking. Participants will receive menus, recipes and some foods for three months, followed by self-maintenance of the diet. Clinical markers will be evaluated before and after the intervention/control periods and six months after ending their intervention period. Primary outcome is ApoB.

The NUTRA study aims to generate evidence to guide the design of dietary interventions for patients with rheumatoid arthritis. By understanding the potential role of diet in reducing both disease activity and cardiovascular risk, the study may contribute to improved treatment strategies for this challenging patient group.

Read the detailed description

NUTRA population and recruitment. Approximately 120 women and men aged 18-85 years with diagnosed RA will be recruited in the Gothenburg region. Approximately 42-48 evaluable participants per randomized group provide 80% power to detect a 15% between-group difference in ApoB after three months at a two-sided α=0.05. Stable treatment and no planned changes in antirheumatic or lipid-affecting medication during the primary period limit pharmacological confounding. Recruitment follows established rheumatology pathways; detailed eligibility criteria are governed by the approved protocol.

Randomization and intervention. Participants are randomized to an immediate three-month intervention or a waiting-list control for three months before receiving the same dietary intervention. The intervention follows NNR2023 and combines food provision with structured, individualized support to facilitate sustainable change. The waiting-list design preserves a randomized comparison while ensuring that all participants are offered the intervention.

Data collection. Baseline and three-month assessments include fasting blood samples, clinical phenotype, blood pressure, joint examination, body composition by dual-energy X-ray absorptiometry, physical function and quality-of-life questionnaires, weighed dietary records and a Food Frequency Questionary (FFQ). Adherence is evaluated from dietary data and selected biomarkers. Samples are stored for metabolomics and inflammatory profiling. The simplified six-month after intervention end follow-up consists of fasting routine blood lipids only, minimizing participant burden while retaining a clinically meaningful maintenance outcome.

Outcomes and analysis. ApoB is the primary outcome. Secondary outcomes include LDL and HDL cholesterol, triglycerides, total cholesterol, disease activity measured by the Disease Activity Score in 28 joints using erythrocyte sedimentation rate (DAS28-ESR), and European Alliance of Associations for Rheumatology (EULAR) response and remission. Olink Target 96 Inflammation characterizes inflammatory profiles; metabolomics supports exploratory response and predictor analyses. The primary analysis follows intention-to-treat principles, comparing randomized groups at three months with baseline adjustment. Mixed-effects models will account for repeated measurements where appropriate. Inflammatory analyses will address multiple testing. Predictor analyses will be exploratory, with model complexity constrained by sample size and internal validation used to assess overfitting.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • nutrition
  • diet
  • nordic nutrition recommendations
  • inflammation
  • metabolomics
  • cardiovascular risk factors
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed RA on Methotrexate and/or additional treatment. RA is defined according to the criteria from EULAR/American College of Rheumatology (ACR) 2010.
  • 18.5-40 kg/m2
  • willing to follow the intervention diet

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • lactation
  • diagnosis for cancer or other life-threatening diseases
  • diabetes type 1 and 2
  • inflammatory bowel disease or celiac disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Immediate healthy diet intervention based on the NNR 2023

    Diet following the Nordic Nutrition Recommendations 2023

    Other: Healthy diet based on NNR2023

  • Experimental
    Delayed dietary intervention based on the NNR2023 (waiting-list control)

    Habitual diet for 3 months followed by healthy diet based on NNR2023 for 3 months

    Other: Healthy diet based on NNR2023 · Other: Control/waiting-list

Interventions

  • OtherHealthy diet based on NNR2023

    Personalized diet- the participants will get individual advice how to adapt their habitual diet to the Nordic Nutrition Recommendations 2023

  • OtherControl/waiting-list

    Habitual diet during the waiting-period/control followed by healthy diet based on NNR2023

06

What researchers measure

Primary outcomes

  1. Apolipoprotein B

    Time frame: 3 months dietary intervention and at 9 months follow up

Secondary outcomes

  1. Patterns of serum inflammatory markers

    Olink Target 96 Inflammation panel will be analysed and multivariate method (OPLS-DA) will be used to evaluate changes in the inflammatory markers between intervention and control.

    Time frame: 3 months dietary intervention

  2. Remission yes/no

    Based on disease activity score -28 joints-erythrocyte sediment rate (DAS28-ESR) and European League Against Rheumatism (EULAR) criteria

    Time frame: 3 months dietary intervention

  3. Disease activity DAS28-CRP

    based on disease activity score -28 joints-c-reactive protein (DAS28-CRP)

    Time frame: 3 months dietary intervention

  4. triacylglycerides

    Time frame: 3 months dietary intervention and at 9 months follow up

  5. high density lipoprotein

    HDL

    Time frame: 3 months dietary intervention and at 9 months follow up

  6. Low density lipoprotein (LDL)

    Time frame: 3 months dietary intervention and at 9 months follow up

  7. total cholesterol

    Time frame: 3 months dietary intervention and at 9 months follow up

  8. Erythrocyte sediment rate (ESR)

    Time frame: 3 months dietary intervention and at 9 months follow up

  9. high sensitive-C-reactive protein (hs-CRP)

    Time frame: 3 months dietary intervention and at 9 months follow up

  10. Corticosteroid use

    Participants will note the use of corticosteroids. A decrease could indicate less pain. Changes is also important to adjust for in analysis of effects on inflammation markers.

    Time frame: 3 months dietary intervention and at 9 months follow up

  11. Physical disability

    Based on the questionnaire HAQ THE HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) DISABILITY INDEX (DI) There are 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). Total score is divided to the number of categories and the range of the index is thus 0-3p.

    Time frame: 3 months dietary intervention and at 9 months follow up

  12. Quality of life (RAND-SF36)

    Self-reported quality of life based on the questionnaire 36-Item Short Form Survey Instrument (SF-36) from RAND (Research and Development- non profit organisation). It taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. Scale is 0-100. Higher score indicates better quality of life.

    Time frame: 3 months dietary intervention and at 9 months follow up

  13. Disease activity score DAS28-ESR

    Disease activity score based on 28 joints and erythrocyte sediment rate (ESR)

    Time frame: 3 months dietary intervention

Other outcomes

  1. Body mass index (BMI)

    Patients are not advised to actively try to loose weight, but do not have to try to keep their weight either. BMI will be a descriptive measure.

    Time frame: 3 months dietary intervention and at 9 months follow up

  2. Patterns of metabolites

    Metabolites analysed by NMR or LC-MS/GC-MS for metabolomics studies (changes in patterns of metabolites). This outcome will mainly be used to evaluate compliance to the intervention diet. Metabolite patterns will be compared by multivariate methods such as OPLS-DA. This outcome will also be used at baseline for descriptives of the participants i.e. habitual lifestyle and diet.

    Time frame: 3 months dietary intervention

  3. Body composition

    Dual x ray absorptiometry (DXA) at baseline and 9 months Descriptive/for adjustment and relative to both diet and eventual changes in physical activity

    Time frame: screening only

  4. European League Against Rheumatism (EULAR) criteria for disease activity

    Based on Disease Activity Score -28 joints -Erythrocyte sediment rate. This can be used to classify patients as good, moderate or non-responders, using the individual amount of change in the DAS and the DAS value (low, moderate, or high) reached. Classes can be used to explore differences in baseline metabolomics, gut microbiota and body composition.

    Time frame: 3 months dietary intervention

  5. Differences in changes in fatty acid patterns in plasma

    Fatty acids will be analysed in plasma and patterns of fatty acids will be analysed and changes in fatty acid patterns during intervention and control will be compared with multivariate methods as a marker for compliance to the diets.

    Time frame: 3 months dietary intervention

  6. Differences in changes in fatty acid patterns in erythrocytes

    Fatty acids will be analysed in erythrocytes and changes in fatty acid patterns during intervention and control will be compared with multivariate methods as a marker for compliance to the diets.

    Time frame: 3 months dietary intervention

07

Study locations

1 site
  • Klinisk Reumatologiskt Forskningscentrum, Sahlgrenska University Hospital
    Gothenburg, 405 30, Sweden
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2028, 46 months after the start.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 46 months is above that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 18, 2025
StartActual
Feb 25, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
150→120
Oct 23, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Editednewly diagnosed RA (within 3 months) that have started on Methotrexate and/or cortisoneadditional treatment. RA is defined according to the criteria from EULAR/American College of Rheumatology (ACR) 2010.
Oct 23, 2026
Interventions
Changed REK-diet→Healthy diet based on NNR2023. Added Control/waiting-list; removed RICH-diet. Arm changed Nutrition recommendations (REC)→Immediate healthy diet intervention based on the NNR 2023. Arms added: Delayed dietary intervention based on the NNR2023 (waiting-list control); arms removed: Nutrient rich diet, (RICH)
Oct 23, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Patterns of serum inflammatory markersNow Apolipoprotein BTime frame: 3 months dietary intervention → 3 months dietary intervention and at 9 months follow up
Oct 23, 2026
Secondary outcomes
1 edited, 5 time frame changed
What changed in the outcomes
  • ChangedBefore Apolipoprotein B100Now Patterns of serum inflammatory markersTime frame: 3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
  • Time frameRemission yes/no3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
  • Time frameDisease activity DAS28-CRP3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
  • Time frameDisease activity score DAS28-ESR3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
  • Time frameother outcomeBody composition9 months follow up → screening only
  • Time frameother outcomeEuropean League Against Rheumatism (EULAR) criteria for disease activity3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Enrollment 150→120
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Editednewly diagnosed RA (within 3 months) that have started on Methotrexate and/or cortisoneadditional treatment. RA is defined according to the criteria from EULAR/American College of Rheumatology (ACR) 2010.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Patterns of serum inflammatory markersNow Apolipoprotein BTime frame: 3 months dietary intervention → 3 months dietary intervention and at 9 months follow up
    Secondary outcomes 1 edited, 5 time frame changed
    What changed in the outcomes
    • ChangedBefore Apolipoprotein B100Now Patterns of serum inflammatory markersTime frame: 3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
    • Time frameRemission yes/no3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
    • Time frameDisease activity DAS28-CRP3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
    • Time frameDisease activity score DAS28-ESR3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
    • Time frameother outcomeBody composition9 months follow up → screening only
    • Time frameother outcomeEuropean League Against Rheumatism (EULAR) criteria for disease activity3 months dietary intervention and at 9 months follow up → 3 months dietary intervention
    Interventions Changed REK-diet→Healthy diet based on NNR2023. Added Control/waiting-list; removed RICH-diet. Arm changed Nutrition recommendations (REC)→Immediate healthy diet intervention based on the NNR 2023. Arms added: Delayed dietary intervention based on the NNR2023 (waiting-list control); arms removed: Nutrient rich diet, (RICH)
    + 3 other changes: index terms, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06831331
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Feb 25, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion